Terms: = Skin cancer AND FANCC, ENSG00000158169, 2176, RP11-80I15_2, FAC, FA3, FACC, FLJ14675 AND Clinical Outcome
531 results:
1. clinical determinants of clinical response to Sonidegib in advanced basal cell carcinoma: a monocenter experience.
Spallone G; Carbone A; Sperati F; Frascione P; Eibenschutz L
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2923-2928. PubMed ID: 38639529
[TBL] [Abstract] [Full Text] [Related]
2. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
3. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial.
Alves Costa Silva C; Piccinno G; Suissa D; Bourgin M; Schreibelt G; Durand S; Birebent R; Fidelle M; Sow C; Aprahamian F; Manghi P; Punčochář M; Asnicar F; Pinto F; Armanini F; Terrisse S; Routy B; Drubay D; Eggermont AMM; Kroemer G; Segata N; Zitvogel L; Derosa L; Bol KF; de Vries IJM
Nat Commun; 2024 Feb; 15(1):1633. PubMed ID: 38395948
[TBL] [Abstract] [Full Text] [Related]
4. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract] [Full Text] [Related]
5. Real-world experience of implementing the MOLES score in a virtual choroidal naevi clinic at a tertiary referral centre.
Rees NOT; Schimansky S; Bizley G; Kobayter L
Eye (Lond); 2024 Apr; 38(6):1183-1188. PubMed ID: 38057559
[TBL] [Abstract] [Full Text] [Related]
6. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
[TBL] [Abstract] [Full Text] [Related]
7. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
8. Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
Gambichler T; Iordanou M; Becker JC; Susok L
Melanoma Res; 2024 Feb; 34(1):80-83. PubMed ID: 37924529
[TBL] [Abstract] [Full Text] [Related]
9. Unexpected clinical outcome for Myxoinflammatory Fibroblastic Sarcoma, When Should They Be Considered High Grade?
Sparkman BK; Nguyen TVV; Smith SC; Bear HD
J Investig Med High Impact Case Rep; 2023; 11():23247096231205344. PubMed ID: 37840277
[TBL] [Abstract] [Full Text] [Related]
10. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR; Di Giacomo AM; Caruso FP; Covre A; Mortarini R; Scala G; Costa MC; Coral S; Fridman WH; Sautès-Fridman C; Brich S; Pruneri G; Simonetti E; Lofiego MF; Tufano R; Bedognetti D; Anichini A; Maio M; Ceccarelli M
Nat Commun; 2023 Sep; 14(1):5914. PubMed ID: 37739939
[TBL] [Abstract] [Full Text] [Related]
11. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract] [Full Text] [Related]
12. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
13. Emilin2 fosters vascular stability by promoting pericyte recruitment.
Fejza A; Camicia L; Carobolante G; Poletto E; Paulitti A; Schinello G; Di Siena E; Cannizzaro R; Iozzo RV; Baldassarre G; Andreuzzi E; Spessotto P; Mongiat M
Matrix Biol; 2023 Sep; 122():18-32. PubMed ID: 37579864
[TBL] [Abstract] [Full Text] [Related]
14. Effect of lidocaine spray on reliving non-coring needle puncture-related pain in patients with totally implantable venous access port: a randomized controlled trial.
Zhu Y; Niu S; Zhang Y; Zhang H; Chang J; Ye L
Support Care Cancer; 2023 Jul; 31(8):452. PubMed ID: 37421451
[TBL] [Abstract] [Full Text] [Related]
15. BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors.
Mandalà M; Palmieri G; Ludovini V; Baglivo S; Marasciulo F; Castiglione F; Gili A; Osella Abate S; Rubatto M; Senetta R; Avallone G; Ribero S; Romano L; Pimpinelli N; de Giorgi V; Roila F; Pisano M; Casula M; Manca A; Sini MC; Massi D; Quaglino P;
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):1991-1998. PubMed ID: 37335879
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic factors of Pretreatment Magnetic Resonance Imaging for Predicting clinical outcome in Patients With Parotid Gland cancer.
Ando T; Kato H; Shibata H; Ogawa T; Noda Y; Hyodo F; Matsuo M
J Comput Assist Tomogr; 2023 May-Jun 01; 47(3):507-513. PubMed ID: 37185018
[TBL] [Abstract] [Full Text] [Related]
17. Flap perfusion assessment with indocyanine green angiography in deep inferior epigastric perforator flap breast reconstruction: A systematic review and meta-analysis.
Wang Z; Jiao L; Chen S; Li Z; Xiao Y; Du F; Huang J; Long X
Microsurgery; 2023 Sep; 43(6):627-638. PubMed ID: 37165852
[TBL] [Abstract] [Full Text] [Related]
18. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.
Garcia-Donas J; Martínez-Urbistondo D; Velázquez Kennedy K; Villares P; Barquin A; Dominguez A; Rodriguez-Moreno JF; Caro E; Suarez Del Villar R; Nistal-Villan E; Yagüe M; Ortiz M; Barba M; Ruiz-Llorente S; Quiralte M; Zanin M; Rodríguez C; Navarro P; Berraondo P; Madurga R
Front Immunol; 2023; 14():1156603. PubMed ID: 37143685
[TBL] [Abstract] [Full Text] [Related]
19. Predictive value and accuracy of [
Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669
[TBL] [Abstract] [Full Text] [Related]
20. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G; Marino P; Olive D; Penault-LLorca F; Delord JP; Simon C; Lamrani-Ghaouti A; Sabatier R; Ciccolini J; Boher JM
BMC Cancer; 2023 May; 23(1):393. PubMed ID: 37131154
[TBL] [Abstract] [Full Text] [Related]
[Next]
